Our data support the findings of Reuben and Lee, which reported that the CD4/CD8 ratio of non-metastatic IBC patients was significantly higher than in metastatic IBC patients, because the non-metastatic IBC patients had a significantly greater reduction in CD4+ helper T lymphocytes than healthy controls [28]. The gene discussed is CD4; the disease is inflammatory breast carcinoma.